Latest Conference Articles

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.

The study presented at CMSC 2017 compared the treatments to an interferon.

Telepsychiatry shown to be viable alternative in rural areas with limited access.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Physicians debated the case of a 65-year-old woman with SPMS.

Physicians debated whether they would prescribe the new MS drug to a patient.

Doctors need to conduct clinical trials and define the disease.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Neomi Shah, MD, MPH, studied patients with sleep apnea to uncover its effect on arterial inflammation.

Valerie Page, MB, BCh, FRCA, recounts a study of simvastatin on delirium patients.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

An overview of the newest treatment options for the disease.

An Evaluation of a Project ECHO Mental Health Pilot

Suicide is now the 10th leading cause of death in the US, with over 40,000 people dying by suicide each year, at a cost of about $44B annually.

At CMSC 2017, Aaron Boster, MD, neuroimmunologist for OhioHealth Neurological Clinicians, discussed why he believes there's never been a better time of opportunity for multiple sclerosis patients, and what must be improved in MS diagnosis practice.

Transcranial Magnetic Stimulation (TMS) is getting good results as an adjunctive therapy for patients with major depression who have failed on several antidepressant medications.

The genetic, environmental, and immune factors behind the disease.

Transcranial Magnetic Stimulation (TMS) is an adjunctive therapy for patients with major depression who have failed on several antidepressant medications.

Dr. Melissa Arbuckle explains what neuroscience is and why every practicing psychiatrist should have an understanding and appreciation for this branch of science.

Physicians received an overview of the scope and severity of the disease.

Dr. Stanley Caroff, Emeritus Professor CE of Psychiatry at the Philadelphia VA Medical Center, sits down with MD Magazine to explain what tardive dyskinesia is, and why it's so important for psychiatrists to be aware of this side effect in their patients taking antipsychotic medications. This is the conclusion of a two-part conversation.

What is tardive dyskinesia? Psychiatrists need to be aware of this side effect in their patients taking antipsychotic medications.

One expert discussed the utility of measurement-based care in helping guide clinical decision-making.

Special events can be useful as a recruitment method for medical students.

Michael Wechsler, MD, MMSc, recounts the phase III trial of Mepolizumab on patients with eosinophilic granulomatosis with polyangiitis (EGPA).

ADHD is explained in-depth in this on-the-scene interview.

The APA lecture focused on a model with detail to game theory.